Streptococcal toxic shock syndrome (STSS) is typically caused by *Streptococcus pyogenes* (group A *Streptococcus* \[GAS\]) ([@R1]). Major investigations on host-pathogen interactions have been performed to determine why some persons experience uncomplicated pharyngitis, but STSS develops in others. On a molecular level, mutations in *covS* (a sensor gene of the major virulence regulator CovR/S) have been frequently associated with invasive GAS disease ([@R2]). In 2009, we reported a case of STSS caused by *S. agalactiae* (group B *Streptococcus* \[GBS\]) and *covS* mutation ([@R3]). Here, we reassess those findings in a larger collection of GBS isolates causing STSS.

We tested 26 GBS isolates from 25 patients (22 adults, 3 children) ([Table](#T1){ref-type="table"}) that were pooled from 3 countries; the United States (22 strains collected 2004--2005), Germany (1 strain, 2006), and Switzerland (2 strains, 2005). For 1 of the 2 case-patients from Switzerland, 2 isolates (same clone) were available for mutation analyses (patient 23 \[[@R4]\]). The isolate from our previously published case report (Sweden, 2005 \[[@R3]\]) served as a control strain for molecular analyses; the corresponding case-patient was included in the demographic analyses (i.e., 26 patients: 23 adults, 3 children). The median age of the included adult patients was 59 years (interquartile range 45.5--68 years); mortality rate was 35% (8/23). The ages of the 3 children were 0, 30, and 60 days (1 death).

###### GBS isolates collected from patients with STSS, showing results of capsular and multilocus sequence typing

  Patient no.     Isolate no.   Patient age   Outcome    Capsular serotype   Sequence type   covR/S mutation
  --------------- ------------- ------------- ---------- ------------------- --------------- -----------------
  1               BSU286        65 y          Died       II                  22              --
  2               BSU287        71 y          Survived   Ia                  23              --
  3               BSU288        46 y          Died       V                   1               --
  4               BSU289        46 y          Survived   IV                  397             --
  5               BSU290        43 y          Survived   V                   1               --
  6               BSU291        35 y          Died       III                 19              --
  7               BSU292        76 y          Survived   V                   1               --
  8               BSU293        48 y          Survived   Ia                  23              --
  9               BSU294        61 y          Died       V                   1               --
  10              BSU295        45 y          Survived   V                   1               --
  11              BSU296        63 y          Died       Ib                  8               --
  12              BSU297        0 d           Survived   Ia                  23              --
  13              BSU298        70 y          Survived   V                   1               --
  14              BSU299        60 y          Survived   V                   1               --
  15              BSU300        73 y          Survived   V                   1               --
  16              BSU301        66 y          Died       III                 17              --
  17              BSU302        2 mo          Survived   III                 17              --
  18              BSU303        94 y          Survived   V                   23              Yes
  19              BSU304        1 mo          Died       Ia                  23              --
  20              BSU305        34 y          Survived   V                   1               --
  21              BSU306        59 y          Survived   IV                  2               --
  22              BSU307        79 y          Died       Ia                  88              --
  23 (*4*)        BSU865, VS    38 y          Survived   II                  19              --
                  BSU866, BC                             --                  --              --
  24              BSU869        32 y          Died       Ib                  8               --
  25              BSU870        53 y          Survived   Ia                  23              --
  Control (*3*)   BSU871        50 y          Survived   Ib                  8               Yes

\*BC, blood culture; GBS, group B *Streptococcus*; STSS, streptococcal toxic shock syndrome; VS, vaginal swab; --, not found.

We used standard molecular biology techniques for nucleic acid preparation and analysis. We performed molecular typing by multilocus sequence typing (MLST) as described ([@R5]) and capsular typing by using latex agglutination and PCR serotype determination ([@R6]) ([Table](#T1){ref-type="table"}). To analyze the *cov* gene locus, we amplified the genes *covS* and *covR* by PCR ([Technical Appendix](#SD1){ref-type="local-data"} Table). Resulting PCR products underwent DNA sequencing with internal *cov* primers on an ABI PRISM 310 Genetic Analyzer (Applied Biosystems, Weiterstadt, Germany).

Nucleotide sequence analysis showed that, in 1 of the strains (from patient 18), both genes, the sensor histidine kinase *covS* and the response regulator *covR*, had mutated. In *covR,* at nucleotide position 242, cytosine was replaced by thymine, leading to an amino acid exchange from alanine to valine. In addition, the *covS* gene of this strain showed a 1-bp deletion of adenine at position 895 of the gene, causing a frame shift and leading to a truncated CovS with a stop codon at nucleotide position 926 of the gene. In the control strain that harbored a 3-bp deletion, our previously published finding was confirmed ([@R3]). In the remaining strains, *cov* alleles matched the gene sequences of completely sequenced GBS strains in the GenBank database (NEM316, 2603V/R, 909A).

During the past few decades, the overall incidence of invasive GBS infections has increased substantially. This trend is particularly noticeable in the elderly and in persons with co-morbid conditions ([@R7]). Our results regarding age distribution of patients, mortality rate, and frequencies of different GBS serotypes are in line with results of previous studies. Twelve (52%) of 23 patients were [\>]{.ul}59 years old. The mortality rate for group B STSS ([\>]{.ul}30%) was similar to that reported for group A STSS ([@R1]). In a previous case series, which included 13 patients with group B STSS, the mortality rate was 23% (3/13) ([@R8]). Three-quarter of our strains (19/26 strains) were attributed to serotype V or Ia/Ib. Large epidemiologic studies have frequently implicated serotype s Ia/Ib, III, and V GBS isolates in the etiology of invasive disease in adults ([@R9]). Apart from sequence type (ST) 1 and ST23 (15/26 strains), the distribution of MLSTs among the GBS isolates was heterogeneous. The highly virulent GBS lineage ST17 was found in only 2 patients (1 adult and 1 child).

The role of *covR/S* mutations in the switch from colonization to invasion has been demonstrated for GAS in a mouse model ([@R2]). Consistent with these findings, GAS strains isolated from STSS patients frequently carry mutations in this operon ([@R10]). Similarly, a 3-bp deletion in the *covR* gene was detected in a GBS strain that caused STSS and necrotizing fasciitis ([@R3]). However, our investigations on a larger collection of GBS isolates did not confirm a high *cov* mutation rate. Only 1 of 25 GBS clones demonstrated a mutation. From 1 patient, a colonizing and invasive isolate (same clone) was available ([@R4]); that isolate showed no mutation in *covR/S*.

Our results should be interpreted with caution because the absolute number of included patients is small, and the cases were pooled from various centers. Nonetheless, Ikebe et al. found *covR/S* mutations in 76 (46.3%) of 164 GAS strains causing STSS and in only 1.7% of 59 strains without invasive disease ([@R10]). In light of these results, the low frequency of mutations found in our collection is surprising. Yet, the association with *covR/S* mutations and GBS TSS in a case report has been shown previously and confirmed here. However, GBS harbors multiple 2-component systems and stand-alone regulators. Our findings indicate that different virulence regulators may be involved in the pathogenesis of fulminant GBS disease.

###### Technical Appendix

Primers used in study of group B streptococcal toxic shock syndrome and *covS/R* mutations.
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